CClinicalTrials.gg
CompletedNCT03278522Updated Mar 9, 2018

Ramosetron Pre-treatment for PONV and QT Prolongation

A Phase 4 interventional study of Ramosetron in PONV and Prolonged QTc Interval, sponsored by Konkuk University Medical Center. Completed at 1 site in Korea, Republic of. Open to female participants aged 19 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-03-09.

Sponsored by Konkuk University Medical Center · Phase 4, Interventional, and Prevention

Phase
Phase 4
Study type
Interventional
Enrollment
64
Allocation
Randomized
Ages
19 Years to 99 Years
Sex
Female
01

Study summary

Ramosetron is commonly used to prevent postoperative nausea and vomiting (PONV) in the Eastern Asia. The prolongation of QTc interval is a main side effect. In this study, the pre-treatment time of ramosetron to decrease PONV, and QTc prolongation is compared.

Read the detailed description

This prospective study evaluate 42 female patients who underwent laparoscopic gynecologic surgery under general anesthesia. Group I (n=21) receive 0.6mg of ramosetron at anesthesia induction. Group R (n=21) received the same at the end of surgery. PONV is evaluated at arrival to post-anesthetic care unit (PACU), before induction, discharge from PACU, 24-, 48-, and 72- after discharge from PACU. The QTc interval is checked before anesthesia, at arrival to PACU, and 24-h after discharge from PACU.

Forty two subjects are needed with an α value of 0.05, a power of 0.8, and effect size difference of 0.9.

02

Conditions studied

  • PONV
  • Prolonged QTc Interval

Keywords

  • ramosetron
03

Who can participate

Ages eligible
19 Years to 99 Years
Sexes eligible
Female
Accepts healthy volunteers
No

Inclusion criteria

  • patients who underwent laparoscopic gynecologic surgery

Exclusion criteria

Exclusion Criteria:

  • preoperative bradyarrhythmia in ECG
04

Study design

Phase
Phase 4
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
64 participants (actual)

Study arms

  • Active comparator
    ramosetron iv at induction (I)

    0.6mg of ramosetron is given to the patients intravenously at anesthesia induction

    Drug: Ramosetron

  • Active comparator
    ramosetron iv at recovery (R)

    0.6mg of ramosetron is given to the patients intravenously at end of surgery

    Drug: Ramosetron

Interventions

  • DrugRamosetron

    Intravenous ramosetron 0.6mg is given to the patients at the induction of anesthesia, or at the end of surgery

    Also known as: ramosetron pre-treatment

05

What researchers measure

Primary outcomes

  1. QTc interval change

    Difference of QTc interval from preoperative value

    Time frame: within 10 min after arrival at PACU, and 24 hour after discharge from PACU

06

Study locations

1 site
  • Lee Sung Ho
    Seoul, 05030, Korea, Republic of
07

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

08

Registry details

Key details

Study ID
NCT03278522
Lead sponsor
Konkuk University Medical Center
Responsible party
Ka Young Rhee (Associate Professor, Konkuk University Medical Center) — Principal investigator
First posted
Sep 11, 2017
Start date
Jul 1, 2017
Primary completion
Feb 28, 2018
Completion
Feb 28, 2018
Last update
Mar 9, 2018

Study contacts

Ka Young Rhee, MD,PhD
principal investigator · Konkuk University Medical Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion